Steminent Biotherapeutics Inc. (TPEX:7729)
Taiwan
· Delayed Price · Currency is TWD 78.50
-4.20 (-5.08%)
Apr 29, 2026, 2:00 PM CST
Steminent Biotherapeutics Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Net Income | -174.04 | -158.75 | -129.23 | -85.47 | -124.2 | Upgrade
|
| Depreciation & Amortization | 30.92 | 16.43 | 12.06 | 9.43 | 11.33 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | - | -0 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | - | 0.46 | Upgrade
|
| Stock-Based Compensation | 11.79 | 15.88 | 8.58 | 2.72 | 0.63 | Upgrade
|
| Other Operating Activities | -1.06 | 5.85 | -0.64 | -0.19 | 53.32 | Upgrade
|
| Change in Accounts Receivable | -0 | - | 0.1 | 0.65 | -0.55 | Upgrade
|
| Change in Inventory | -1.91 | -10.12 | -4.19 | 6.93 | 0.2 | Upgrade
|
| Change in Accounts Payable | 0.31 | 0.39 | 0.23 | 1.28 | -0.21 | Upgrade
|
| Change in Unearned Revenue | - | - | -0.46 | -0.64 | 1.02 | Upgrade
|
| Change in Other Net Operating Assets | 1.68 | -9.1 | -1.25 | -3.9 | 2.9 | Upgrade
|
| Operating Cash Flow | -132.31 | -139.41 | -114.81 | -69.2 | -55.11 | Upgrade
|
| Capital Expenditures | -7.76 | -87.15 | -27.46 | -2.32 | -0.6 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | - | 0 | Upgrade
|
| Sale (Purchase) of Intangibles | - | -1.22 | -0.25 | -0.19 | - | Upgrade
|
| Investment in Securities | 11.6 | -11.6 | - | - | - | Upgrade
|
| Other Investing Activities | - | - | -0.84 | 0.01 | 0.05 | Upgrade
|
| Investing Cash Flow | 3.84 | -99.97 | -28.56 | -2.5 | -0.55 | Upgrade
|
| Long-Term Debt Issued | 25.73 | - | - | - | - | Upgrade
|
| Long-Term Debt Repaid | -12.18 | -11.64 | -6.84 | -7.45 | -7.64 | Upgrade
|
| Net Debt Issued (Repaid) | 13.55 | -11.64 | -6.84 | -7.45 | -7.64 | Upgrade
|
| Issuance of Common Stock | 408.97 | 4.15 | 450.26 | 2.02 | 251.6 | Upgrade
|
| Other Financing Activities | - | - | -1.46 | - | 1.46 | Upgrade
|
| Financing Cash Flow | 422.52 | -7.49 | 441.95 | -5.43 | 245.42 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.27 | 0.42 | -0.16 | 0 | -0.02 | Upgrade
|
| Net Cash Flow | 293.78 | -246.46 | 298.43 | -77.13 | 189.75 | Upgrade
|
| Free Cash Flow | -140.07 | -226.57 | -142.27 | -71.52 | -55.71 | Upgrade
|
| Free Cash Flow Margin | - | - | -15119.02% | -11245.28% | -2626.69% | Upgrade
|
| Free Cash Flow Per Share | -2.38 | -4.05 | -2.94 | -1.61 | -1.58 | Upgrade
|
| Cash Interest Paid | 2.15 | 1.92 | 1.78 | 0.9 | 1.33 | Upgrade
|
| Cash Income Tax Paid | -0.01 | 0.36 | 0.25 | 0.06 | -0.07 | Upgrade
|
| Levered Free Cash Flow | -68.96 | -170.31 | -88.67 | -45.36 | -32.43 | Upgrade
|
| Unlevered Free Cash Flow | -67.62 | -169.12 | -87.55 | -44.8 | -31.6 | Upgrade
|
| Change in Working Capital | 0.08 | -18.83 | -5.58 | 4.32 | 3.36 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.